These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39279643)

  • 1. Enteroids to Study Pediatric Intestinal Drug Transport.
    Streekstra EJ; Keuper-Navis M; van den Heuvel JJMW; van den Broek P; Stommel MWJ; de Boode W; Botden S; Bervoets S; O'Gorman L; Greupink R; Russel FGM; van de Steeg E; de Wildt SN
    Mol Pharm; 2024 Oct; 21(10):4983-4994. PubMed ID: 39279643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human enteroid monolayers as a potential alternative for Ussing chamber and Caco-2 monolayers to study passive permeability and drug efflux.
    Streekstra EJ; Keuper-Navis M; van den Heuvel JJMW; van den Broek P; Stommel MWJ; Bervoets S; O'Gorman L; Greupink R; Russel FGM; van de Steeg E; de Wildt SN
    Eur J Pharm Sci; 2024 Oct; 201():106877. PubMed ID: 39154715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and age-dependent differences in absorption.
    Streekstra EJ; Kiss M; van den Heuvel J; Nicolaï J; van den Broek P; Botden SMBI; Stommel MWJ; van Rijssel L; Ungell AL; van de Steeg E; Russel FGM; de Wildt SN
    Clin Transl Sci; 2022 Oct; 15(10):2392-2402. PubMed ID: 35962572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of enteroids derived from children and adults to study age-dependent differences in intestinal CYP3A4/5 metabolism.
    Streekstra EJ; Keuper-Navis M; van den Heuvel JJWM; van den Broek P; Greupink R; Stommel MWJ; de Boode WP; Botden SMBI; Russel FGM; van de Steeg E; de Wildt SN
    Eur J Pharm Sci; 2024 Oct; 201():106868. PubMed ID: 39084538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-Specific ADME Gene Expression in Infant Intestinal Enteroids.
    Streekstra EJ; Scheer-Weijers T; Bscheider M; Fuerst-Recktenwald S; Roth A; van Ijzendoorn SCD; Botden S; de Boode W; Stommel MWJ; Greupink R; Russel FGM; van de Steeg E; de Wildt SN
    Mol Pharm; 2024 Sep; 21(9):4347-4355. PubMed ID: 39120063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Evaluation System Using Intestinal Organoids for Drug Efflux Transport Analysis by an Imaging Approach.
    Koseki C; Ishikawa T; Sato Y; Shimada M; Yokoi Y; Nakamura K; Honma N; Moriyama T; Kashiwagi H; Sugawara M
    J Pharm Sci; 2024 Sep; 113(9):2675-2682. PubMed ID: 38871222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Hepatic and Intestinal Efflux Transport of Statins.
    Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
    Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
    Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
    Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
    Dahan A; Sabit H; Amidon GL
    AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
    Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
    Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Basis and Differentiation-Associated Alterations of Anion Secretion in Human Duodenal Enteroid Monolayers.
    Yin J; Tse CM; Avula LR; Singh V; Foulke-Abel J; de Jonge HR; Donowitz M
    Cell Mol Gastroenterol Hepatol; 2018; 5(4):591-609. PubMed ID: 29930980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib.
    Long A; Yamamiya I; Valentine M; Machnes Z; Hangai N; Anderson B; Wacheck V; Gao L
    Clin Transl Sci; 2024 Sep; 17(9):e70012. PubMed ID: 39258521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.
    Sechaud R; Gu H; Rahmanzadeh G; Chiparus O; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):535-547. PubMed ID: 39110203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
    Mishra J; Simonsen R; Kumar N
    J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
    Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
    Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
    Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
    Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
    Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockout Transporter Cell Lines to Assess Substrate Potential Towards Efflux Transporters.
    Volpe DA
    AAPS J; 2024 Jul; 26(4):79. PubMed ID: 38981917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
    Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.